Literature DB >> 14961586

Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid.

Séverine Colas1, Lénaic Paon, Fabrice Denis, Marie Prat, Pascal Louisot, Claude Hoinard, Olivier Le Floch, Gregory Ogilvie, Philippe Bougnoux.   

Abstract

Dietary docosahexaenoic acid (DHA), which integrates into tumor cell membranes, has been reported to enhance the efficacy against tumors of cytotoxic drugs that induce reactive oxygen species (ROS). Because ionizing radiation also generate ROS, we initiated a study to determine whether dietary DHA might sensitize mammary tumors to irradiation. Mammary tumors were induced by N-methylnitrosourea (NMU) in Sprague-Dawley rats. The optimal dose of radiation to examine the effect of DHA on tumor response to irradiation was determined to be 18 grays (Gy) using a 4-6 MeV electron beam (according to the depth of the target volume) delivered in a single fraction from a linear accelerator. Two groups of rats were fed a basal diet containing 7% of a mixture of peanut and rapeseed oils enriched with 8% of an oil containing either a low (palm oil) or high (DHASCO oil containing 40% DHA) DHA content. DHA group was equally subdivided into 2 groups without or with addition of vitamin E (100 IU/kg diet). Irradiation was carried out when the first tumor in each rat reached 1.5 cm2 and subsequent change in tumor size was documented over time. DHA level in adipose tissue, taken as a biomarker, was higher in the DHA supplemented group compared to the control group. Vitamin E level in liver, the best storage for this compound, was higher in the vitamin E supplemented DHA group compared to the DHA group. Tumor size decreased by 60% at 12 days after irradiation in the DHA group vs. 31% in the control group (p = 0.03) and 36% in the DHA plus vitamin E group. Therefore, dietary DHA sensitized mammary tumors to radiation. The addition of vitamin E inhibited the beneficial effect of DHA, suggesting that this effect might be mediated by oxidative damage to the peroxidizable lipids. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14961586     DOI: 10.1002/ijc.11725

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Determinants of DHA incorporation into tumor tissue during dietary DHA supplementation.

Authors:  Nawale Hajjaji; Valérie Schubnel; Philippe Bougnoux
Journal:  Lipids       Date:  2011-06-03       Impact factor: 1.880

2.  Omega-3 fatty acid supplementation in cancer therapy : does eicosapentanoic acid influence the radiosensitivity of tumor cells?

Authors:  Katrin Manda; Stephan Kriesen; Guido Hildebrandt; Rainer Fietkau; Gunther Klautke
Journal:  Strahlenther Onkol       Date:  2011-01-18       Impact factor: 3.621

3.  Dietary beta-carotene inhibits mammary carcinogenesis in rats depending on dietary alpha-linolenic acid content.

Authors:  Virginie Maillard; Claude Hoinard; Khelifa Arab; Marie-Lise Jourdan; Philippe Bougnoux; Véronique Chajès
Journal:  Br J Nutr       Date:  2006-07       Impact factor: 3.718

Review 4.  Diet, cancer, and the lipidome.

Authors:  Philippe Bougnoux; Bruno Giraudeau; Charles Couet
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-03       Impact factor: 4.254

5.  RBC and WBC fatty acid composition following consumption of an omega 3 supplement: lessons for future clinical trials.

Authors:  Theodore R Witte; Alexander J Salazar; Oscar F Ballester; W Elaine Hardman
Journal:  Lipids Health Dis       Date:  2010-03-22       Impact factor: 3.876

6.  Suppression of PPARβ, and DHA treatment, inhibit NaV1.5 and NHE-1 pro-invasive activities.

Authors:  Ramez Wannous; Emeline Bon; Ludovic Gillet; Julie Chamouton; Günther Weber; Lucie Brisson; Jacques Goré; Philippe Bougnoux; Pierre Besson; Sébastien Roger; Stephan Chevalier
Journal:  Pflugers Arch       Date:  2014-07-15       Impact factor: 3.657

Review 7.  Pharmaceutical nanoformulation strategies to spatiotemporally manipulate oxidative stress for improving cancer therapies - exemplified by polyunsaturated fatty acids and other ROS-modulating agents.

Authors:  Rui Xue Zhang; Franky Fuh-Ching Liu; Hoyin Lip; Junhong Liu; Qianrong Zhang; Xiao Yu Wu
Journal:  Drug Deliv Transl Res       Date:  2022-01-22       Impact factor: 5.671

8.  Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial.

Authors:  P Bougnoux; N Hajjaji; M N Ferrasson; B Giraudeau; C Couet; O Le Floch
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

Review 9.  Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio.

Authors:  Marike W van Gisbergen; Emma Zwilling; Ludwig J Dubois
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

Review 10.  Emerging strategies to target cancer metabolism and improve radiation therapy outcomes.

Authors:  Martin Kery; Ioanna Papandreou
Journal:  Br J Radiol       Date:  2020-06-23       Impact factor: 3.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.